J. Goldman & CO LP Vertex Pharmaceuticals Inc Call Options Transaction History

J. Goldman & CO LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $2.81 Million - $3.37 Million	8,200 New	8,200 $3.34 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $15.7 Million - $17.7 Million	55,000 New	55,000 $15.9 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $1.33 Million - $1.68 Million	7,500 New	7,500 $1.65 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $6.32 Million - $7.45 Million	-33,700 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $6.98 Million - $8.13 Million	33,700 New	33,700 $7.24 Million

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.